Rocket Pharmaceuticals (RCKT) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $2.36, +6.79% vs the prior close of $2.21.
- Volume 1.88M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
RCKT jumps 6.8% to $2.36. Closed at $2.36, +6.79% vs the prior close of $2.21. Day range $2.21–$2.39, opened at $2.22.
RCKT daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — RCKT jumps 6.8% to $2.36
- Closed at $2.36, +6.79% vs the prior close of $2.21. Day range $2.21–$2.39, opened at $2.22.
- Volume was 1.88M shares, 1.0x its 50-day average of 1.82M.
- Price is -26.6% vs its 50-day average ($3.21) and -33.0% vs its 200-day average ($3.52).
- 52-week range $2.18–$5.45; today's close sits at 6% of that range, 56.7% below the 52-week high.
Oct 14, 2026 — RCKT slides 3.9% to $2.21, a 52-week low, 4 down days in a row
- Closed at $2.21, -3.91% vs the prior close of $2.30. Day range $2.18–$2.30, opened at $2.26.
- Volume was 2.01M shares, 1.1x its 50-day average of 1.82M.
- Price is -31.7% vs its 50-day average ($3.24) and -37.4% vs its 200-day average ($3.53).
- 52-week range $2.18–$5.45; today's close sits at 1% of that range, 59.4% below the 52-week high.
- That makes 4 straight losses.
Oct 13, 2026 — RCKT slides 7.3% to $2.30, a 52-week low on 2.2x normal volume
- Closed at $2.30, -7.26% vs the prior close of $2.48. Day range $2.26–$2.55, opened at $2.47.
- Volume was 3.89M shares, 2.2x its 50-day average of 1.81M — unusually heavy trading.
- Price is -29.5% vs its 50-day average ($3.26) and -34.9% vs its 200-day average ($3.54).
- 52-week range $2.26–$5.45; today's close sits at 1% of that range, 57.8% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — RCKT slides 3.1% to $2.48
- Closed at $2.48, -3.12% vs the prior close of $2.56. Day range $2.46–$2.60, opened at $2.54.
- Volume was 2.30M shares, 1.3x its 50-day average of 1.79M.
- Price is -24.5% vs its 50-day average ($3.28) and -30.0% vs its 200-day average ($3.54).
- 52-week range $2.42–$5.45; today's close sits at 2% of that range, 54.5% below the 52-week high.
Oct 9, 2026 — RCKT dips 2.7% to $2.56 on 1.9x normal volume
- Closed at $2.56, -2.66% vs the prior close of $2.63. Day range $2.54–$2.69, opened at $2.59.
- Volume was 3.37M shares, 1.9x its 50-day average of 1.74M — unusually heavy trading.
- Price is -22.3% vs its 50-day average ($3.30) and -27.8% vs its 200-day average ($3.55).
- 52-week range $2.42–$5.45; today's close sits at 5% of that range, 53.0% below the 52-week high.
Oct 8, 2026 — RCKT jumps 3.7% to $2.63 on 2.0x normal volume
- Closed at $2.63, +3.75% vs the prior close of $2.54. Day range $2.52–$2.78, opened at $2.78.
- Volume was 3.46M shares, 2.0x its 50-day average of 1.70M — unusually heavy trading.
- Price is -20.5% vs its 50-day average ($3.31) and -25.9% vs its 200-day average ($3.55).
- 52-week range $2.42–$5.45; today's close sits at 7% of that range, 51.7% below the 52-week high.
Oct 7, 2026 — RCKT rises 2.2% to $2.54
- Closed at $2.54, +2.22% vs the prior close of $2.48. Day range $2.42–$2.64, opened at $2.45.
- Volume was 2.81M shares, 1.7x its 50-day average of 1.67M.
- Price is -23.6% vs its 50-day average ($3.32) and -28.7% vs its 200-day average ($3.55).
- 52-week range $2.42–$5.45; today's close sits at 4% of that range, 53.5% below the 52-week high.
Oct 6, 2026 — RCKT slides 5.0% to $2.48, a 52-week low
- Closed at $2.48, -4.98% vs the prior close of $2.61. Day range $2.46–$2.62, opened at $2.61.
- Volume was 1.79M shares, 1.1x its 50-day average of 1.66M.
- Price is -25.6% vs its 50-day average ($3.33) and -30.3% vs its 200-day average ($3.56).
- 52-week range $2.46–$5.45; today's close sits at 1% of that range, 54.5% below the 52-week high.
- SEC filings that day: 8-K.
Oct 5, 2026 — RCKT rises 2.0% to $2.61
- Closed at $2.61, +1.95% vs the prior close of $2.56. Day range $2.50–$2.63, opened at $2.59.
- Volume was 1.66M shares, 1.0x its 50-day average of 1.65M.
- Price is -22.0% vs its 50-day average ($3.35) and -26.7% vs its 200-day average ($3.56).
- 52-week range $2.50–$5.45; today's close sits at 4% of that range, 52.1% below the 52-week high.
Oct 2, 2026 — RCKT dips 1.2% to $2.56, a 52-week low
- Closed at $2.56, -1.16% vs the prior close of $2.59. Day range $2.53–$2.66, opened at $2.64.
- Volume was 1.82M shares, 1.1x its 50-day average of 1.65M.
- Price is -23.8% vs its 50-day average ($3.36) and -28.2% vs its 200-day average ($3.57).
- 52-week range $2.51–$5.45; today's close sits at 2% of that range, 53.0% below the 52-week high.
RCKT latest news & SEC filings
Every SEC filing by or about RCKT in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 3.02 — Sold unregistered shares.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Wilson Martin sold 75,364 shares at $3.40 (≈$256.24K) on Sep 11, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 15, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 14, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 11, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 11, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 2, 2026 · Form 25-NSE — Notice that a security is being removed from exchange listing
Notice that a security is being removed from exchange listing
Aug 27, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Wilson Martin sold 631 shares at $3.38 (≈$2.13K) on Aug 18, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 10, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $0 (prior year $0)
- Net income: $123.21M (prior year -$68.92M) (swung to profit vs Jun 30, 2025)
- Diluted EPS: $1.08 (prior year -$0.62) (swung to profit vs Jun 30, 2025)
Aug 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 31, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 14, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Things to know before you trade RCKT
- Last results release: Aug 10, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 26, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 9, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.78% (largest 10.9%). That is a volatile stock.
- Liquidity: about 2.33M shares (≈$5.50M) trade per day on average.
- 52-week position: $2.36 vs a range of $2.18–$5.45 (6% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 1 open-market buys, 24 sales; latest: Martin Wilson sold 75,364 shares on Sep 11, 2026.
- Latest filings: 8-K Oct 6, 2026; 8-K Sep 15, 2026; 8-K Aug 27, 2026.
- Share count: 109.77M shares outstanding (Jul 31, 2026), +1.7% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
RCKT market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 2.22 | 2.39 | 2.21 | 2.36 | 1.88M |
| Oct 14, 2026 | 2.26 | 2.30 | 2.18 | 2.21 | 2.01M |
| Oct 13, 2026 | 2.47 | 2.55 | 2.26 | 2.30 | 3.89M |
| Oct 12, 2026 | 2.54 | 2.60 | 2.46 | 2.48 | 2.30M |
| Oct 9, 2026 | 2.59 | 2.69 | 2.54 | 2.56 | 3.37M |
| Oct 8, 2026 | 2.78 | 2.78 | 2.52 | 2.63 | 3.46M |
| Oct 7, 2026 | 2.45 | 2.64 | 2.42 | 2.54 | 2.81M |
| Oct 6, 2026 | 2.61 | 2.62 | 2.46 | 2.48 | 1.79M |
| Oct 5, 2026 | 2.59 | 2.63 | 2.50 | 2.61 | 1.66M |
| Oct 2, 2026 | 2.64 | 2.66 | 2.53 | 2.56 | 1.82M |
| Oct 1, 2026 | 2.62 | 2.74 | 2.58 | 2.59 | 2.09M |
| Sep 30, 2026 | 2.62 | 2.73 | 2.55 | 2.63 | 2.53M |
| Sep 29, 2026 | 2.63 | 2.65 | 2.56 | 2.59 | 1.15M |
| Sep 28, 2026 | 2.57 | 2.62 | 2.51 | 2.61 | 2.07M |
| Sep 25, 2026 | 2.80 | 2.80 | 2.57 | 2.60 | 2.63M |
| Sep 24, 2026 | 3.00 | 3.03 | 2.66 | 2.69 | 4.38M |
| Sep 23, 2026 | 3.33 | 3.34 | 2.95 | 3.02 | 2.78M |
| Sep 22, 2026 | 3.29 | 3.41 | 3.28 | 3.35 | 1.07M |
| Sep 21, 2026 | 3.40 | 3.40 | 3.27 | 3.27 | 1.36M |
| Sep 18, 2026 | 3.47 | 3.56 | 3.35 | 3.37 | 1.60M |
About Rocket Pharmaceuticals
Rocket Pharmaceuticals (RCKT) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEW YORK, NY. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1281895.
RCKT board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Carsten Boess | Director | Jul 6, 2026 |
| Elisabeth Bjork | Director | Jan 6, 2026 |
| Mikael Dolsten | Director | Jul 6, 2026 |
| Peter Fong | Director | Jul 6, 2026 |
| Fady Ibraham Malik | Director | Jul 6, 2026 |
| David P Southwell | Director | Aug 5, 2026 |
| Roderick Wong | Director | Jul 6, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Sarbani Chaudhuri | See Remarks | Aug 13, 2026 |
| Joseph Manhede | Principal Accounting Officer | Jul 8, 2026 |
| John Militello | See Remarks | May 28, 2026 |
| Syed Ali-Aamir Rizvi | Chief Medical Officer | Feb 13, 2026 |
| Jonathan David Schwartz | See Remarks | Nov 20, 2025 |
| Gaurav Shah | CEO | Aug 20, 2026 |
| Christopher James Stevens | Chief Operating Officer | Aug 13, 2026 |
| Martin Wilson | General Counsel | Sep 15, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 11, 2026 | Martin Wilson | Sale | 75,364 | $3.40 |
| Aug 18, 2026 | Martin Wilson | Sale | 631 | $3.38 |
| Aug 18, 2026 | Gaurav Shah | Sale | 2,293 | $3.38 |
| Aug 13, 2026 | Gaurav Shah | Sale | 2,837 | $3.38 |
| Aug 13, 2026 | Martin Wilson | Sale | 3,493 | $3.38 |
| Aug 11, 2026 | Christopher James Stevens | Sale | 36,658 | $3.50 |
| Aug 11, 2026 | Sarbani Chaudhuri | Sale | 4,701 | $3.50 |
| May 21, 2026 | Gaurav Shah | Sale | 55,684 | $3.09 |
| May 19, 2026 | John Militello | Sale | 384 | $3.01 |
| May 19, 2026 | Martin Wilson | Sale | 662 | $3.01 |
| May 19, 2026 | Gaurav Shah | Sale | 2,409 | $3.01 |
| May 13, 2026 | Martin Wilson | Sale | 3,361 | $3.61 |
| May 13, 2026 | Gaurav Shah | Sale | 2,728 | $3.61 |
| May 13, 2026 | John Militello | Sale | 855 | $3.61 |
| May 7, 2026 | Sarbani Chaudhuri | Sale | 17,650 | $3.84 |
RCKT financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $0 | $-223.12M | -2.01 | $-190.01M |
| Dec 31, 2024 | $0 | $-258.75M | -2.73 | $-209.72M |
| Dec 31, 2023 | $0 | $-245.59M | -2.92 | $-194.92M |
| Dec 31, 2022 | $0 | $-221.86M | -3.26 | $-178.14M |
| Dec 31, 2021 | $0 | $-169.07M | -2.67 | $-121.16M |
Latest balance sheet: total assets $423.10M, total liabilities $54.27M, cash $224.51M (as of Jun 30, 2026).
RCKT earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 10, 2026 | 8-K Item 2.02 (results) | $3.64 |
| May 7, 2026 | 8-K Item 2.02 (results) | $3.67 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $4.53 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $3.23 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $3.09 |
| May 8, 2025 | 8-K Item 2.02 (results) | $7.04 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $9.40 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $17.25 |
| Aug 5, 2024 | 8-K Item 2.02 (results) | — |
| May 6, 2024 | 8-K Item 2.02 (results) | — |
| Feb 26, 2024 | 8-K Item 2.02 (results) | — |
| Feb 27, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on RCKT
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.